Moberg Pharma Comments on the Results of the North American Phase 3 Study With MOB-015 |
| December 12, 2019 | December 2019 Bond Updates |
|
STOCKHOLM, Dec. 12, 2019 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB): On Monday the topline results were presented from the first study in the Phase 3 program for MOB-015, where the primary endpoint and the two key secondary endpoints were met. Since the results are somewhat contradictory... |
| View more at: https://www.prnewswire.com:443/news-releases/moberg-pharma-comments-on-the-results-of-the-north-american-phase-3-study-with-mob-015-300973809.html |
| Related News |
|